NCT07473700

Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease

An Open-Label Study to Assess the Hemodynamic Effect and the Safety of TX000045 After 16 Weeks of Treatment in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 25 (estimated)
• Sponsor: Tectonic Operating Company, Inc. · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The primary purpose of this study is to assess the effect of TX000045 on pulmonary vascular resistance (PVR) in participants with pulmonary hypertension secondary to interstitial lung disease (PH-ILD) and to assess the safety and tolerability of TX000045 in participants with PH-ILD.

Conditions

• Hypertension, Pulmonary
• Lung Diseases, Interstitial

Interventions

Type	Name	Description
DRUG	TX000045	Subcutaneous Injection.

Timeline

• Start date: 2026-03-30
• Primary completion: 2027-11-21
• Completion: 2027-12-11
• First posted: 2026-03-16
• Last updated: 2026-03-16

Locations

6 sites across 5 countries: United States, Poland, Romania, Serbia, Spain

Regulatory

• FDA-regulated drug study